Could a new pill slow Alzheimer's? early trial begins

NCT ID NCT07236190

Recruiting now Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called NPC-1 (made of two natural compounds) in 40 adults aged 55+ with early Alzheimer's, mild cognitive impairment, or subjective memory concerns. The goal is to see if it safely changes blood markers linked to Alzheimer's brain changes. Participants take the drug for a set period, and researchers compare their blood tests before and after treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction subjective cognitive decline

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE MILD COGNITIVE IMPAIRMENT (MCI) SUBJECTIVE COGNITIVE COMPLAINTS (SCCS) SUBJECTIVE COGNITIVE DECLINE (SCD)

Contacts and locations

Locations

Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02129, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.